Company: NCEL
Filing Date: 2025-03-31
Form Type: 425
Source: 0001213900-25-025889
Chunk: 48

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: 425
Chunk 48
---
, to the personal jurisdiction of each the State of New York and United States
Federal court sitting in New York County (each, a “”) and has validly and irrevocably waived any objection
to the laying of venue of any suit, action or proceeding brought in any such court; and the Company has the power to designate, appoint
and empower, and pursuant to this Agreement, has legally, validly, effectively and irrevocably designated, appointed and empowered, the
authorized agent identified on for service of process in any action arising out of or relating to this Agreement,
or the offering of the Securities in any New York Court, and service of process effected on any such authorized agent will be effective
to confer valid personal jurisdiction over the Company as provided in this Agreement.

(fff) . This
Agreement is in proper form under the laws of Switzerland for the enforcement thereof against the Company, and to ensure the legality,
validity, enforceability or admissibility into evidence in Switzerland of this Agreement, it is not necessary that this Agreement be filed
or recorded with any court or other authority in Switzerland or, except as disclosed in the most recent SEC Reports, that any stamp or
similar tax in Switzerland be paid on or in respect of this Agreement or any other documents to be furnished hereunder. Any final judgment
for a fixed or readily calculable sum of money rendered by a New York Court having jurisdiction under its own domestic laws in respect
of any suit, action or proceeding against the Company based upon this Agreement and any instruments or agreements entered into for the
consummation of the transactions contemplated herein and therein would be declared enforceable against the Company, without re-examination
or review of the merits of the cause of action in respect of which the original judgment was given or re-litigation of the matters adjudicated
upon, by the courts of Switzerland. The Company is not aware of any reason why the enforcement in Switzerland of such a New York Court
judgment would be, as of the date hereof, contrary to public policy of Switzerland.

(ggg) .
The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still
pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all applicable laws, rules
and regulations and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical
study and clinical trials of new drugs and biologics as